RTP Mobile Logo
Select Publications

Bardia A et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol 2021;32(6):746-56. Abstract

Camidge DR et al. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). ASCO 2022;Abstract 9016.

Drago JZ et al. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021;18(6):327-44. Abstract

Garassino MC et al. EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) versus docetaxel in patients with non-small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors. ASCO 2022;Abstract TPS9149.

Garon EB et al. EVOKE-02: A phase 2 study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC). ASCO 2022;Abstract TPS9146.

Garon EB et al. TROPION-PanTumor01: Updated results from the NSCLC cohorts of the phase 1 study of datopotamab deruxtecan in solid tumors. IASLC 2021;Abstract MA03.02.

Goto et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial. ESMO 2022;Abstract LBA55.

Janne PA et al. Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures. ASCO 2021;Abstract 9015.

Jänne PA et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov 2022;12(1):74-89. Abstract

Levy B et al. TROPION-Lung02: Initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC. ISACL 2022;Abstract MA13.07.

Li BT et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med 2022;386(3):241-51. Abstract